Effects of Testosterone Treatment in Older Men.

BACKGROUND Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials--the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. RESULTS Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P=0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. CONCLUSIONS In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.).

[1]  B. Dawn,et al.  Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. , 2015, European heart journal.

[2]  S. Resnick,et al.  Recruitment and Screening for the Testosterone Trials. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[3]  A. Isidori,et al.  Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis , 2014, Expert opinion on drug safety.

[4]  M. Budoff,et al.  Title Erratum : The Testosterone Trials : Seven coordinated trials of testosterone treatment in elderly men , 2014 .

[5]  S. Greenland,et al.  Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men , 2014, PloS one.

[6]  G. Grunwald,et al.  Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. , 2013, JAMA.

[7]  B. Cowling,et al.  Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials , 2013, BMC Medicine.

[8]  M. Pencina,et al.  Sex Hormone–Binding Globulin, but Not Testosterone, Is Associated Prospectively and Independently With Incident Metabolic Syndrome in Men , 2011, Diabetes Care.

[9]  A. Jette,et al.  Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. , 2011, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  M. Pencina,et al.  Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  G. B. Phillips Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[12]  S. Roberts,et al.  Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  H. Vesper,et al.  Interlaboratory comparison study of serum total testoserone measurements performed by mass spectrometry methods , 2009, Steroids.

[14]  A. Silman,et al.  Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[16]  J. Bergquist,et al.  High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. , 2008, American journal of clinical pathology.

[17]  F. Goldstein,et al.  Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. , 2007, Journal of andrology.

[18]  J. Mulhall,et al.  Analysis of the efficacy and safety of sildenafil citrate in the geriatric population , 2007, BJU international.

[19]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[20]  R. Casaburi,et al.  Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  A. Matsumoto,et al.  Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. , 2005, The Journal of clinical endocrinology and metabolism.

[22]  G. Alexander,et al.  A simple self-report diary for assessing psychosexual function in hypogonadal men. , 2003, Journal of andrology.

[23]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[24]  J. Cappelleri,et al.  The International Index of Erectile Function (IIEF): a state-of-the-science review , 2002, International Journal of Impotence Research.

[25]  E. Metter,et al.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  J. Berlin,et al.  Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.

[27]  D A Redelmeier,et al.  Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. , 1997, American journal of respiratory and critical care medicine.

[28]  D. Follmann,et al.  An approximate generalized linear model with random effects for informative missing data. , 1995, Biometrics.

[29]  R. Little Pattern-Mixture Models for Multivariate Incomplete Data , 1993 .

[30]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[31]  D. Watson,et al.  Development and validation of brief measures of positive and negative affect: the PANAS scales. , 1988, Journal of personality and social psychology.

[32]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[33]  D R Taves,et al.  Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.

[34]  D. Blazer,et al.  Testosterone and aging : clinical research directions , 2004 .

[35]  J. Ware SF-36 health survey: Manual and interpretation guide , 2003 .

[36]  R. Spitzer,et al.  The PHQ-9: validity of a brief depression severity measure. , 2001, Journal of general internal medicine.

[37]  L. Derogatis The Derogatis Interview for Sexual Functioning (DISF/DISF-SR): an introductory report. , 1997, Journal of sex & marital therapy.